AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in ...

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

According to the 2008 World Health Organization (WHO) classification system for hematologic cancers, the primary myelodysplastic syndromes are one of five major categories of myeloid neoplasms ...

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematologic disorders, which are characterized by abnormal cellular maturation resulting in cytopenias and a variable risk ...